351 related articles for article (PubMed ID: 25796589)
1. A case of C3 glomerulonephritis successfully treated with eculizumab.
Payette A; Patey N; Dragon-Durey MA; Frémeaux-Bacchi V; Le Deist F; Lapeyraque AL
Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589
[TBL] [Abstract][Full Text] [Related]
2. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
3. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
[TBL] [Abstract][Full Text] [Related]
4. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
Fernandez-Ruiz R; Blank RB; Wu M; Belmont HM
Lupus; 2021 Sep; 30(10):1671-1678. PubMed ID: 34192954
[TBL] [Abstract][Full Text] [Related]
5. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab and recurrent C3 glomerulonephritis.
Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
[TBL] [Abstract][Full Text] [Related]
9. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
[TBL] [Abstract][Full Text] [Related]
11. Pathology after eculizumab in dense deposit disease and C3 GN.
Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
[TBL] [Abstract][Full Text] [Related]
12. Successful Treatment of Posttransplant Recurrent Complement C3 Glomerulopathy with Eculizumab.
Sahin H; Gok Oguz E; Akoglu H; Atilgan G; Ulusal Okyay G; Karaveli Gursoy G; Kip Teymur T; Ertoy D; Canbakan B; Ayli MD
Iran J Kidney Dis; 2018 Oct; 12(5):315-318. PubMed ID: 30367025
[TBL] [Abstract][Full Text] [Related]
13. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
Alexander MP; Fervenza FC; De Vriese AS; Smith RJH; Nasr SH; Cornell LD; Herrera Hernandez LP; Zhang Y; Sethi S
J Nephrol; 2016 Apr; 29(2):203-209. PubMed ID: 26187133
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
Kim JS; Foster KW; Westphal SG
Clin Nephrol; 2020 Jan; 93(1):51-56. PubMed ID: 31661064
[TBL] [Abstract][Full Text] [Related]
15. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
[TBL] [Abstract][Full Text] [Related]
16. Crescentic acute glomerulonephritis with isolated C3 deposition: a case report and review of literature.
Mao S; Xuan X; Sha Y; Zhao S; Zhang A; Huang S
Int J Clin Exp Pathol; 2015; 8(2):1826-9. PubMed ID: 25973075
[TBL] [Abstract][Full Text] [Related]
17. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
[TBL] [Abstract][Full Text] [Related]
18. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL
Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143
[TBL] [Abstract][Full Text] [Related]
19. Eculizumab in Pediatric Dense Deposit Disease.
Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
